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Background & Aims: Childhood-onset inflamma-
tory bowel disease (IBD) might be etiologically dif-
ferent from adult-onset IBD. We analyzed disease
phenotypes and progression of childhood-onset
disease and compared them with characteristics of
adult-onset disease in patients in Scotland.
Methods: Anatomic locations and behaviors were
assessed in 416 patients with childhood-onset (276
Crohn’s disease [CD], 99 ulcerative colitis [UC], 41
IBD type unclassified [IBDU] diagnosed before sev-
enteenth birthday) and 1297 patients with adult-
onset (596 CD, 701 UC) IBD using the Montreal
classification. Results: At the time of diagnosis in
children, CD involved small bowel and colon (L3) in
51% (138/273), colon (L2) in 36%, and ileum (L1) in 6%;
the upper gastrointestinal (GI) tract (L4) was also af-
fected in 51%. In 39%, the anatomic extent increased
within 2 years. Behavioral characteristics progressed;
24% of children developed stricturing or penetrating
complications within 4 years (vs 9% at diagnosis; P <
.0001; odds ratio [OR], 3.32; 95% confidence interval
[CI], 1.86–5.92). Compared with adults, childhood-on-
set disease was characterized by a “panenteric” pheno-
type (ileocolonic plus upper GI [L3L4]; 43% vs 3%; P<
.0001; OR, 23.36; 95% CI, 13.45–40.59) with less isolated
ileal (L1; 2% vs 31%; P < .0001; OR, 0.06; 95% CI,
0.03–0.12) or colonic disease (L2; 15% vs 36%; P< .0001;
OR, 0.31; 95% CI, 0.21–0.46). UCwas extensive in 82% of
the children at diagnosis, versus 48% of adults (P <
.0001; OR, 5.08; 95% CI, 2.73–9.45); 46% of the children
progressed to develop extensive colitis during follow-
up. Forty-six percent of children with CD and 35% with
UC required immunomodulatory therapy within 12
months of diagnosis. The median time to first surgery
was longer in childhood-onset than adult-onset patients
with CD (13.7 vs 7.8 years; P< .001); the reverse was true
for UC. Conclusions: Childhood-onset IBD is charac-
terized by extensive intestinal involvement and rapid
early progression.
The inflammatory bowel diseases (IBD), Crohn’s dis-ease (CD) and ulcerative colitis (UC), are complex
polygenic diseases, and are a major cause of morbidity in
Europe and North America, where up to 1 in 250 of the
general population are affected.1 The direct economic
costs are estimated as £720 million per year for patients
in the United Kingdom.1,2
As many as 25% of patients first present during child-
hood or adolescence.3 In children, these diseases have
been marked by a steady rise in incidence over the last 4
decades, with disease presenting most commonly imme-
diately before the start of the teenage years, thereby
impacting on emotional and physical development as
well as affecting linear growth, education, and future
employment prospects.4
It has remained a topic of great debate whether child-
hood-onset disease is etiologically distinct from adult-
onset disease—a debate recently catalyzed by the search
for susceptibility genes in CD and UC. Clinical experi-
ence, including the early requirement for second-line
immunomodulatory drugs5,6 in childhood-onset disease,
suggests that childhood-onset disease may have a more
“severe” phenotype. This hypothesis has been supported
to some extent by the limited available data suggesting
that childhood-onset CD may be characterized by exten-
sive intestinal involvement at presentation.7–9 However,
rigorous studies investigating the progression of intesti-
nal involvement and behavior in childhood disease are
not available to help explore this hypothesis further.
Abbreviations used in this paper: CI, conﬁdence interval; IBDU,
inﬂammatory bowel disease type unclassiﬁed; OR, odds ratio.
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In contrast with childhood-onset disease, the develop-
ment of internationally accepted disease classification
systems in recent years has facilitated longitudinal stud-
ies addressing changes in disease phenotype in adults
with IBD.10 A series of careful studies have consistently
demonstrated the stability of disease location over time,
as well as the progression of the behavior phenotype
from purely inflammatory disease to either stricturing or
penetrating disease.11 The most recent classification sys-
tem, proposed by the Montreal working party, attempted
to integrate the increasing knowledge basis that had
evolved since previous groups in Rome and Vienna had
addressed these issues.12 Although best considered a
work in progress, the Montreal classification has formed
the basis of phenotypic classification in many published
adult clinical and genetic studies since 2005.
In the present study, we have described the presenting
phenotype and progression of disease phenotype in child-
hood-onset CD and UC. We have used the phenotypic
subclassification system for disease behavior and location
suggested in the report of the Montreal working party,12
and we have used the age of16 years at diagnosis to define
childhood-onset disease (A1 in the Montreal classification).
We also studied the phenotype of IBD in the subgroup of
children diagnosed in early childhood—before the eighth
birthday. We evaluated the need for immunosuppressive
medication and surgery in childhood-onset disease, and
compared time to first surgery in childhood-onset and
adult-onset IBD. Finally, we assessed whether the pheno-
type of childhood-onset IBD may be different from adult-
onset IBD by comparing these phenotypic characteristics in
the Scottish population.
Methods
Subjects
We recruited 416 children with IBD diagnosed
before their seventeenth birthday from all the pediatric
gastroenterology centers in Scotland as part of an ongo-
ing childhood-onset IBD genetics project from July 2002.
Children were investigated according to the ESPGHAN
“Porto”-criteria for diagnosis of IBD.13,14 Detailed patient
demographics are presented in Table 1. We also recruited
1297 patients with adult-onset IBD from the Gastroen-
terology Department at Western General Hospital, Edin-
burgh from January 2000 as part of an ongoing IBD
genetics project. Detailed demographics are presented in
Table 1.
The study was approved by the local Research Ethics
Committee. Informed personal or parental consent was
obtained.
Classification of IBD
The diagnosis of IBD was based on standard cri-
teria as set out by Lennard–Jones.15 All patients were
phenotyped using the Montreal classification (Table 2),
which has addressed some of the difficulties of previous
systems in classifying pediatric IBD: a childhood-onset
category was introduced (17 years at diagnosis) and the
Vienna classification was modified so that upper gastro-
intestinal (GI) disease could “coexist” with lower GI lo-
cations of disease.12,16 A dedicated database manager
(H.E.D.) performed quality control of phenotypic data
entered onto a Microsoft Access database (Microsoft Cor-
poration, Redmond, WA). Oral CD was defined by mac-
roscopic/biopsy changes after examination by a pediatric
dentist/oral medicine specialist only.
We scored the progression of anatomic involvement
of the GI tract and disease behavior in 2-yearly inter-
vals to 4 years in childhood-onset CD. Adult-onset CD
location was assessed at last clinical follow-up and
adult-onset CD behavior was analyzed after 5 years
clinical follow-up. Childhood-onset and adult-onset
UC were assessed at diagnosis and at last clinical fol-
low-up. When comparing childhood-onset and adult-
Table 1. Demographics of IBD Patients With Childhood-Onseta and Adult-Onsetb Inflammatory Bowel Disease
Childhood IBD (n  416) CD UC IBDU
N 276 99 41
Male/female 164/112 48/51 19/22
Median age at diagnosis (y) (Q1–Q3) 11.5 (8.9–13.2) 10.9 (8.8–10.8) 10 (7.6–12.5)
Caucasian 97.8% (270/276) 94.9% (94/99) 97.5% (40/41)
Median duration of follow-up (y) (Q1–Q3) 3.7 (1.7–6.0) 3.5 (1.1–4.8) 2.5 (0.4–4.1)
Smoking at diagnosis (all IBD) (yes/no/ex-smoker) 1.6%/95.3%/3.1%
Adult IBD (n  1297) CD UC
n 596 701
Male/female 216/380 342/359
Median age at diagnosis (y) (Q1–Q3) 29.7 (23.7–43.5) 34.5 (26.0–50.0)
Caucasian 99.3% (578/582) 97.3% (673/688)
Median duration of follow-up (y) (Q1–Q3) 10.3 (3.8–20.6) 8.9 (4.2–16.5)
Smoking at diagnosis (yes/no/ex-smoker) 43.9%/44.4%/11.7% 19.2%/49.9%/30.9%
IBDU, IBD type unclassified.
aAge 17 years at diagnosis; Montreal A1.
bAge 17 years at diagnosis; Montreal A2–A3.
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onset IBD, the location was defined as the maximum
extent by the time of last follow-up but before the first
resection.12
In addition to the 4 disease locations described in the
Vienna classification (ileal, colonic, ileocolonic, and up-
per GI [L1–L4]) the Montreal classification added 3 fur-
ther subcategories; these were the first 3 categories (L1–
L3) with the addition of L4 where the disease sites
coexisted, meaning the L4 disease location no longer
negated the presence of often substantial lower GI dis-
ease allowing for more in-depth phenotypic analysis.16
Recognition was given to the fact that enteric and peri-
anal fistulae may represent different disease phenotypes.
Thus, perianal disease was removed from the B3 category
and instead added as a suffix “p” to any of the disease
categories, B1–B3.
In patients with UC disease, extent was divided into 3
categories: E1 for patients with a proctitis (inflammation
limited to the rectum); E2 for left-sided disease distal to
the splenic flexure; and E3 for extensive disease proximal
to the splenic flexure.
Statistical Analysis
To avoid statistical errors generated by multiple
testing, we opted to analyze our data first as contingency
tables consisting of columns of Montreal categories ver-
sus rows of different time points of clinical follow-up.
After this, unifactorial analyses were performed using 2
or Fisher’s exact test (when n  5 per field of 2  2 table)
to calculate odds ratios (OR) and 95% confidence inter-
vals (CI). Minitab software (Release 13.20; Minitab Inc,
State College, PA) and GraphPad Instat software (v 3.06;
San Diego, CA) were used. Kaplan–Meier curves to assess
time from diagnosis to first surgical resection were cal-
culated using GraphPad Prism software (v 4.0). Analysis
of time to use of immunomodulatory drug therapy (first
use of any of azathioprine, methotrexate, or biological
therapy) was also assessed and is presented as a Kaplan–
Meier curve in the childhood-onset group only. Differ-
ences between Kaplan–Meier curves were compared using
a log-rank test automatically calculated in Prism.
Results
Phenotypic Characteristics of
Childhood-Onset CD
CD at diagnosis. CD affected the small as well as
large bowel (L3  L4) in 50.5%, the colon (L2  L4) in
36.3%, and the ileum (L1  L4) in 5.9%. More than half
of children (50.9%) were affected by CD proximal to the
terminal ileum at diagnosis (any L4). Follow-up of 2
years was completed for 196 of 273 patients (71.8%).
Follow-up data of 4 years were available for 132 of 273
patients (48.4%; Table 3).
CD location. The location of disease changed over
time. Detailed analysis of the 196 childhood-onset CD
patients who had 2 years follow-up demonstrated that
a large proportion of these children experienced exten-
sion of anatomic involvement of the GI tract. At diagno-
sis, 53 of 196 (27.0%) already had the maximum disease
extent (L3  L4). Of the 143 children who could there-
fore change CD location at 2 years follow-up, 56 (39.1%)
children did. These changes were due to the inclusion of
findings on upper GI endoscopy in 15 of 56 (26.8%) only;
in the majority (41/56, 73.2%), changes were due to
extension from localized disease to more extensive
disease involving the lower GI tract. This extension of
anatomic involvement was more likely to be due to
increasing ileal involvement over time (27/56 [48.2%]
patients [ileal, 23; ileocolonic, 4]) rather than colonic
involvement with time (11/56 [19.6%]; P  .001; OR,
3.81; 95% CI, 1.64–8.84).
CD behavior. Disease behavior progressed signif-
icantly from diagnosis to 4 years follow-up (P .001). By
2 years follow-up, the behavior of CD changed with an
increase in stricturing disease (perianal) from 4.4% to
Table 2. The Montreal Classification of Crohn’s Disease
Age at diagnosis (y)
A1 16
A2 17–40
A3 40
CD location
L1 Terminal Ileum (TI) L1  L4 TI  upper GI
L2 Colon L2  L4 Colon  upper GI
L3 Ileocolon L3  L4 Ileocolon  upper GI
L4 Upper GI
CD behavior
B1 Nonstricturing, nonpenetrating B1p Nonstricturing, nonpenetrating  perianal
B2 Stricturing B2p Stricturing  Perianal
B3 Penetrating B3p Penetrating  Perianal
UC: Disease extent
E1 Proctitis
E2 Left sided (distal)
E3 Extensive (pancolitis)
C
LIN
IC
A
L–
A
LIM
EN
TA
R
Y
TR
A
C
T
1116 VAN LIMBERGEN ET AL GASTROENTEROLOGY Vol. 135, No. 4
9.6% (P  .02; OR, 0.43; 95% CI, 0.20–0.91) and a de-
crease in inflammatory disease (perianal) from 91.2% to
82.7% (P  .005; OR, 2.16; 95% CI, 1.24–3.78). By 4 years
after diagnosis, both stricturing disease (perianal) and
penetrating disease (perianal) increased from 4.4% to
12.9% (P  .001; OR, 0.31; 95% CI, 0.14–0.67) and from
4.4% to 11.4% (P  .008; OR, 0.36; 95% CI, 0.16–0.79),
respectively. Inflammatory disease (perianal) decreased
from 91.2% at diagnosis to 75.8% (P  .0001; OR, 3.32;
95% CI, 1.86–5.92). Perianal disease increasingly compli-
cated the other behavior phenotypes over time, rising
from 13.9% at diagnosis to 22.2% after 4 years of fol-
low-up (P  .04; OR, 0.57; 95% CI, 0.34–0.98).
Phenotypic Characteristics of
Childhood-Onset UC
UC phenotype was assessed at diagnosis and at
last follow-up (Table 4). Pancolitis/extensive colitis was
present in 74.7% at diagnosis. Of 95 children with child-
hood-onset UC, 73 had follow-up data recorded (median
duration of follow-up, 3.5 years). At last follow-up, the
proportions of disease location had not changed signifi-
cantly. Of the 73 children with follow-up data available,
49 of childhood-onset UC already had the maximum
extent (E3) at diagnosis. Of the 24 who could possibly
increase extent at follow-up, forty-six percent extended
their disease location from less extensive to extensive
colitis/pancolitis (11/24).
Is There a Distinct Phenotype of Childhood
IBD Diagnosed Before 8 Years of Age?
Of 408 participants, 82 (20.1%; 8/416 children
had incomplete data) children were diagnosed with IBD
before their 8th birthday (age cutoff as described by
Heyman et al7; 53 CD [64.6%], 19 UC [23.2%], and 10 IBD
type unclassified [IBDU; 12.2%]). Of the 326 children 8
at the time of diagnosis (79.9%), CD was diagnosed in
220 (67.5%), UC in 78 (23.9%), and IBDU in 28 (8.6%). At
diagnosis in children 8, IBD was more likely to be
localized to the colon (L2UCIBDU) than in older
children (47/82 [57.3%] vs 145/326 [44.5%]; P  .03; OR,
1.68,95% CI, 1.03–2.73). CD presenting at 8 years was
characterized by more isolated colonic disease (L2; 34.0%
vs 17.7%; P .009; OR, 2.39; 95% CI, 1.23–4.64), less ileal
involvement (L1L4 and L3L4, 21/53 [39.6%] vs 133/
220 [60.5%]; P  .006, OR, 0.43; 95% CI, 0.23–0.79) and
less “panenteric” CD (L3L4; 18.9% vs 33.6%;
P  .03; OR, 0.46; 95% CI, 0.22–0.96). CD limited to the
mouth and/or perianal region occurred more commonly
in children 8 years at diagnosis (7/53 [13.2%] vs 6/220
[2.7%]; P  .001; OR, 5.43; 95% CI, 1.74–16.90).
Immunomodulator Use in
Childhood-Onset IBD
The time to use of immunomodulatory drug ther-
apy (first use of any of azathioprine, methotrexate, or
biological therapy) was assessed and presented as Kaplan–
Meier curves in the childhood-onset group only (Figure 1).
Table 3. Comparison of Montreal Disease Location and Behavior at Diagnosis, at Follow-Up of 2 Years and Follow-Up of
4 Years in Childhood-Onset CD Patients
Childhood-onset CD
At diagnosis, n (%)
(N  273)
At follow-up 2 years, n (%)
(N  196)
At follow-up 4 years, n (%)
(N  132)
CD phenotype: Location*
L1 10 (3.7) 5 (2.6) 4 (3.0)
L2 57 (20.9) 30 (15.3) 24 (18.2)
L3 53 (19.4) 32 (16.3) 20 (15.2)
L1  L4 6 (2.2) 4 (2.0) 3 (2.3)
L2  L4 42 (15.4) 32 (16.3) 24 (18.2)
L3  L4 85 (31.1) 86 (43.9) 51 (38.6)
L4 6 (2.2) 2 (1.0) 2 (1.5)
P .61
CD phenotype: Behavior
B1 (p) 215 (no p) (78.8) 136/197 (69.0) 81 (61.4)
249 (p) (91.2) 163/197 (82.7) 100 (75.8)
B2 (p) 9 (no p) (3.3) 14/197 (7.1) 10 (7.6)
12 (p) (4.4) 19/197 (9.6) 17 (12.9)
B3 (p) 11 (no p) (4.0) 14/197 (7.1) 12 (9.1)
12 (p) (4.4) 15/197 (7.6) 15 (11.4)
P .001
*At diagnosis 14 children had oral (n  7)/oralperianal (n  4)/perianal (n  3) disease only. At 2 years of follow-up, 5 children had oral
(n  1)/oralperianal (n  4) disease only. At 4 years of follow-up, 4 children had oral (n  1)/oralperianal (n  3) disease.
Table 4. Comparison of Montreal Disease Location at
Diagnosis and at Last Follow-Up in
Childhood-Onset UC Patients
UC phenotype
At diagnosis
(n  95)
At last follow-up
(n  73) P
E3 71 (74.7%) 60 (82.2%)
E2 20 (21.1%) 12 (16.4%) .39
E1 4 (4.2%) 1 (1.4%)
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These data involve 408 cases, with missing data for the 8
(1.9%) remaining cases. There was a significant difference
between these curves (log-rank test P  .008), with the
median time to any immunomodulator usage 17 months
for CD, 28 months for UC, and 63 months for IBDU. At
120 months of follow-up, the proportion of cases of CD,
UC, and IBDU who had not been exposed to any immu-
nomodulation were 11.5%, 40.5%, and 38.4%, respectively.
Need for Resectional Surgery in
Childhood-Onset and Adult-Onset IBD
Kaplan–Meier curves assessing the time from di-
agnosis to first resection/colectomy are shown for child-
hood-onset and adult-onset CD (data available for n 
585) and UC (data available for n 654; Figures 2 and 3).
Significant differences were seen in the Kaplan–Meier
curves between the childhood-onset and adult-onset co-
horts, in CD and UC (log-rank test P  .001 and P  .03,
respectively).
Among the childhood-onset CD patients, 17.1% re-
quired surgery compared with 52.8% of adult-onset CD
patients (P  .0001; OR, 0.18; 95% CI, 0.13–0.26). Five
years after diagnosis, 20.2% of childhood-onset CD pa-
tients had undergone surgery versus 42.8% of adult onset
CD patients. By 10 years of follow-up, these percentages
were 34.5% and 55.5%, respectively. The median time to
surgery in childhood-onset and adult-onset CD was 13.7
and 7.8 years, respectively (Figure 2).
Of childhood-onset UC patients, 20.0% underwent colec-
tomy compared with 21.7% of adult-onset UC patients (P
.70; OR, 0.90; 95% CI, 0.53–1.54). At 5 years after diagnosis,
26.1% of childhood-onset UC patients had undergone sur-
gery versus 15.5% of adult-onset UC patients. By 10 years of
follow-up, 40.9% of childhood-onset UC patients and 19.9%
of adult-onset UC patients had had a colectomy. Based on
the Kaplan–Meier analysis, the median time to surgery was
11.1 years in childhood-onset UC compared with50 years
in adult-onset UC (Figure 3).
Figure 2. Kaplan–Meier curves showing time from diagnosis to sur-
gery in childhood-onset and adult-onset CD.
Figure 1. Kaplan–Meier curves show-
ing time from diagnosis to first use of im-
munomodulatory drug therapy (any
of azathioprine, 6-mercaptopurine,
methotrexate, or biological therapy)
in the cohort of childhood-onset IBD
patients.
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Comparison of Childhood-Onset and
Adult-Onset IBD: Location and Behavior
Using the Montreal Classification
Phenotypic data on 416 children and 1297 adults
with IBD were compared at the time of last follow-up
(Table 5). In childhood-onset CD, there was a clear male
predominance compared to adult-onset CD (59.4% vs
36.2%; P  .0001; OR, 2.58; 95% CI, 1.92–3.45). UC was
equally likely to occur in both genders in childhood-
onset and adult-onset disease. A family history of IBD (in
any member of the family) was more common in child-
hood-onset than adult-onset disease (33.9% vs 19.6%; P
.0001; OR, 2.11; 95% CI, 1.65–2.69).
Location of CD (defined by the Montreal system as
maximum extent by the time of last follow-up but before
the first resection) showed statistically significant differ-
ences between childhood-onset and adult-onset disease
(P .001). Childhood-onset CD was characterized by less
isolated ileal involvement (L1) 2.6% versus 31.5% (P 
.0001; OR, 0.06; 95% CI, 0.03–0.12) and less isolated
colonic disease (L2) 15.0% versus 36.1% (P  .0001; OR,
0.31; 95% CI, 0.21–0.46). Childhood-onset IBD was char-
acterized by more “panenteric”/extensive CD (L3L4;
43.2% vs 3.2%; P  .0001, OR, 23.36; 95% CI, 13.45–
40.59).
To overcome the confounding factor of different in-
vestigation protocols in adult-onset and childhood-onset
CD with regard to the use of upper GI endoscopy and
small bowel assessment, we also analyzed the location of
CD controlling for involvement of the GI tract proximal
to the terminal ileum (L4) by means of a contingency
table containing the categories L1L4, L2L4, L3L4,
and L4.
The extent of involvement of the GI tract in childhood-
onset CD remained statistically different from adult-
onset CD both when assessed at last follow-up and when
only the patients with a minimum of 5 years follow-up
were included (both P  .001; Supplementary Table 1
[available online at www.gastrojournal.org]). There is a
highly significant association of ileal disease location
with stricturing/penetrating disease behavior and of co-
lonic disease location with inflammatory disease behavior
when disease behavior is stratified for disease location in
both childhood-onset and adult-onset CD after 5 years
follow-up (Supplementary Table 1; P .001). Comparing
disease behavior at 5 years follow-up, the behavior of CD
was similar in the 2 groups (P  .17).
UC in the childhood-onset cohort was more extensive
(P  .001), with extensive colitis (E3) in 82.2% of child-
hood-onset but only 47.6% of adult-onset UC (P .0001;
OR, 5.08; 95% CI, 2.73–9.45).
Discussion
The present study represents not only a detailed
application of the Montreal classification of IBD in a
large cohort of patients with childhood-onset disease,
but also provides new robust data on disease evolution,
as well as need for immunomodulation and surgery in
childhood-onset disease. Rigorous follow-up of 416 chil-
Figure 3. Kaplan–Meier curves showing time from diagnosis to sur-
gery in childhood-onset and adult-onset UC.
Table 5. Comparison of Location and Behavior Between
Childhood-Onset and Adult-Onset IBD Patients
Using the Montreal Classification
Scottish
childhood-onset IBD
Scottish
adult-onset IBD
n 416 1297
At last follow-up
(n  273)
At last follow-up
(n  507)
CD phenotype: Location*
L1 7 (2.6%) 160 (31.5%)
L2 41 (15.0%) 183 (36.1%)
L3 52 (19.0%) 99 (19.5%)
L1  L4 5 (1.8%) 21 (4.1%)
L2  L4 43 (15.8%) 8 (1.6%)
L3  L4 118 (43.2%) 16 (3.2%)
L4 2 (0.7%) 13 (2.6%)
P .001
At 5 years
(n  136)
At 5 years
(n  377)
CD phenotype: Behavior
B1 (p) 99 (72.7%) 249 (66.0%)
B2 (p) 20 (14.7%) 54 (14.3%)
B3 (p) 17 (12.6%) 74 (19.7%)
P .17
At last follow-up
(n  73)
At last follow-up
(n  569)
UC phenotype
E3 60 (82.2%) 271 (47.6%)
E2 12 (16.4%) 201 (35.3%)
E1 1 (1.4%) 97 (17.0%)
P .001
*Five children had oral (n  1)/oralperianal disease (n  4); 7
adults had oral (n  4)/oralperianal (n  1)/perianal (n  2)
disease.
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dren with IBD in the 3 pediatric gastroenterology centers
in Scotland has allowed us to document these aspects,
notably the progression of disease location and behavior.
Data were collected by structured case notes review, and
measures taken to overcome interobserver bias.
A number of our findings are likely to be important
and pertinent both to basic research and to clinical prac-
tice, and may be useful in patient counseling. We have
demonstrated that the presenting phenotype of child-
hood-onset IBD was characterized by extensive anatomic
involvement, with strikingly high rates of panenteric CD
(small bowel, large bowel, and upper GI tract involve-
ment) as well as extensive UC. Furthermore, disease ex-
tent was remarkably dynamic in childhood-onset disease:
Even within 2 years of diagnosis, childhood-onset CD
progressed to more extensive anatomic involvement in
1 in 3 patients. Disease behavior rapidly progressed to
complications of stricture formation or the development
of fistulae. Disease extent in 46% of the few cases of
childhood-onset UC with isolated left-sided disease or
proctitis at diagnosis also showed extension within the
follow-up period.
We have provided compelling evidence for the high
prevalence of an extensive or panenteric disease pheno-
type at presentation in childhood-onset CD. Recent data
from the North American Pediatric IBD Consortium
Registry are consistent with our findings, albeit using a
distinct disease classification system.9 Gupta et al pre-
sented their findings in 600 pediatric CD patients at
diagnosis: 61.5% of children had small bowel and colon
involvement (compared with 50.5% in our study). Baldas-
sano et al17 recently described a small cohort of 142
children with CD: 86% had involvement of the small
bowel and colon ( upper GI tract). Cucchiara et al18
showed in an Italian cohort of pediatric CD patients with
1 year of follow-up (n  200) that 58% had ileocolonic
CD (using the Vienna classification).18
Our data in UC are also consistent with the hypothesis
that childhood-onset disease has a very high bias toward
extensive disease. This observation is also consistent with
other datasets. Previously reported rates of pancolitis in
patients with UC, from prospective childhood studies
(80%–90%)7,19,20 are far higher than those from prospec-
tive adult studies (24% pancolitis21 or 33% extensive co-
litis22). Our study not only provides further replication of
these data, but also directly compares a childhood-onset
and adult-onset cohort within the same population using
the Montreal classification (82% of childhood-onset UC
patients had extensive colitis at last follow-up compared
with 47% of adult-onset UC).
Moreover, we provide evidence that disease phenotypic
characteristics are dynamic, and changeable, rather than
stable, in childhood-onset disease. Detailed analysis of
our patients with childhood-onset CD demonstrated that
the anatomic extent of disease progressed to more exten-
sive involvement soon after diagnosis in 39%. In the vast
majority, these changes were not due to the inclusion of
findings on upper GI endoscopy but rather to progres-
sion from limited disease (oral/perianal [L1, L2, or L4]) to
involve both small and large bowel (L3). In almost 50% of
patients who progressed in anatomic involvement, this
was due to involvement of the ileum. These data contrast
with the stability of disease location repeatedly reported
in adult CD.23,24 Louis et al23 followed 125 adult patients
with CD and found, at 10 years after diagnosis, that only
15% had changed disease location (location was defined
using the Vienna classification). Henriksen et al24 ob-
served a change of (Vienna) CD location in 13.5% after 5
years follow-up (n  200).
In our CD cohort, our data intriguingly suggest het-
erogeneity even within childhood-onset phenotype. We
have shown that involvement of the ileum is age depen-
dent: children 8 years old at the time of diagnosis had
significantly less involvement of the ileum and more
isolated colonic disease than children 8 years at diag-
nosis, confirming previous studies.7,8,25 In a large study of
nearly 1400 North American early-onset patients, Hey-
man et al7 demonstrated by multifactorial analysis that a
colonic predominant phenotype exists in IBD diagnosed
under the age of 8 years. Paul et al8 studied 413 pediatric
IBD patients and also demonstrated a greater tendency
for very young patients to present with colonic disease.
In addition to the dynamic nature of disease location,
we have also demonstrated that childhood-onset CD
behavior was not stable over time: Inflammatory disease
behavior progressed with the development of stricturing/
intestinal penetrating complications. This progression is
also seen in adult-onset disease (Table 5). In the land-
mark study of disease behavior in 2000 CD patients,
Cosnes et al26 demonstrated that 40% had penetrating
disease as defined by the Vienna criteria at 5 years and
70% by 20 years. Similar data from Belgium and Scotland
were reported subsequently.27,28 Detailed analysis of dis-
ease behavior stratified for disease location demonstrated
a highly significant association of stricturing/penetrating
disease complications with ileal CD and of inflammatory
disease with colonic CD (both in childhood-onset and
adult-onset CD; Supplementary Data [available online at
www.gastrojournal.org]).
Direct comparison of the phenotypic characteristics in
adult-onset and childhood-onset disease also emphasized
the extensive intestinal involvement in children, although
these comparisons are limited by the retrospective nature
of the present study. The increased intensity of investi-
gation in childhood-onset disease compared with adult-
onset IBD is noteworthy.13,14,29 This line of argument has
been previously suggested to underlie the high prevalence
of upper GI disease reported in children, when compared
with adults—upper GI endoscopy is rarely performed in
adult IBD assessments and historic (adult) datasets typ-
ically have less small bowel assessment. Notwithstanding
this issue, which is difficult to resolve without a longitu-
C
LIN
IC
A
L–
A
LIM
EN
TA
R
Y
TR
A
C
T
1120 VAN LIMBERGEN ET AL GASTROENTEROLOGY Vol. 135, No. 4
dinal prospective study both in children and adults, anal-
ysis based on the Montreal categories, which treats upper
GI disease as a modifier (ileal, colonic, or ileocolonic
disease each with or without CD proximal to the termi-
nal ileum), confirmed the statistically significant differ-
ences between CD location in childhood-onset and adult-
onset onset CD.
In an attempt to further define the “severity” of child-
hood-onset IBD, we evaluated the need for both immu-
nomodulation and surgery (Figures 1–3). By 12 months
from diagnosis, 45.9% of childhood-onset CD, 37.9% of
IBDU and 35.1% of UC have commenced immunomodu-
lator therapy. However, interpretation of these data as a
surrogate for severity is problematic, and confounded by
multiple factors, most notably the variability amongst
individual physicians in thresholds for the use of these
agents. Physician preferences have undoubtedly changed
in the last decade, both for adults and in children. In-
creasing use of immunomodulatory therapy early in the
course of disease has become a well-established treatment
paradigm in pediatric IBD practice, following the land-
mark publication by Markowitz et al30; in adults, data
from our own center clearly illustrate similar temporal
trends toward early use—significantly higher rates of
6-mercaptopurine/azathioprine usage of 47.9% at 12
months were seen in an inception cohort diagnosed be-
tween 2003 and 2007 compared with a rate of 13.3% in a
cohort diagnosed between 1998 and 2002.31
Many may regard the need for surgery after diagnosis
as a potential “gold-standard” marker of disease severity.
For this reason, we have analyzed need for surgical inter-
vention in our cohort. Intriguingly, these data suggest
that surgical intervention may occur earlier in childhood-
onset UC than in adult-onset UC, but that the opposite
relationship is seen for CD. However, there are multiple
possible confounding variables in using these data as a
surrogate for severity, especially when comparing practice
for children and teenagers with CD against practice in
adults. The more extensive panenteric disease of child-
hood-onset CD may preclude referral for early surgery, as
do the frequently strong reservations of children and
their families concerning early surgical intervention (es-
pecially if formation of a stoma is required). We suggest
that these factors impact significantly on the data in
childhood-onset CD, and lead to the escalation of med-
ical therapy rather than surgery, notwithstanding disease
severity. In UC, the higher surgical rates we demonstrate
in childhood-onset disease are interesting, in the context
of the high prevalence of extensive colonic involvement
in these children, and may well reflect “severity” more
accurately. Notwithstanding these controversies, the dif-
ferent trends in time to first surgery in childhood-onset
CD and UC are of interest and require further evaluation.
The findings of our study may have clinical implica-
tions for management in childhood-onset IBD. It might
be considered that early use of biological agents and
immunosuppressants may ideally be targeted preferen-
tially on children with aggressive disease. However, it is
increasingly apparent that other factors need also be
considered in highlighting either all or a subgroup of
childhood-onset IBD as the group for whom “top-down”
intervention is appropriate—most notably the recent con-
cerns regarding the development of hepatosplenic T-cell
lymphoma in patients treated with combined immuno-
modulation, together with the lack of any evidence-based
strategies for discontinuation of anti-tumor necrosis fac-
tor therapies, or even thiopurines.32
Thus, we propose that the initial application of our
data may be in the translational research setting. Identi-
fying specific laboratory markers of disease susceptibility
or phenotype—genetic, serologic, or proteomic—critically
depends on the availability of an appropriate classifica-
tion system. Our study has applied the Montreal classi-
fication in a large cohort of childhood-onset IBD pa-
tients, and demonstrates the potential usefulness of this
system in studies of pediatric IBD.
Supplementary Data
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2008.06.081.
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